The increased expression of these nuclear transporter proteins, together with their increased interaction with Kpnβ1 in cancer cells, supports studies that indicate that the rate of nuclear-cytoplasmic transport of cargo proteins is higher in cancer cells than in normal cells, and further highlights the potential of targeting this functional pathway as an anti-cancer therapeutic strategy. Here, KPNB1 is linked to cancer.